RADIOPHARM THERANOSTICS LTD
RADXNASDAQTrading Snapshot
- Day Range
- $366.24 – $371.14
- 52-Week Range
- —
- Volume
- $5.48B
- Avg Volume
- $4.75B
- Shares Outstanding
- 3.93B
- Next Earnings
- Dec 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 7.9x
- EPS (TTM)
- —
- Dividend Yield
- —
- Dilution (1yr)
- +0.0%
Why Investors Own RADX
- ✓High-growth profile — revenue up +55.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
RADIOPHARM THERANOSTICS LTD
RADX
StockOtter · stockotter.spaceAbout RADIOPHARM THERANOSTICS LTD
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
RADIOPHARM THERANOSTICS LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift RADX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
RADIOPHARM THERANOSTICS LTD announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.